Answers are grounded in this paper and cite their sources.
The therapeutic efficacy of current treatment strategies for glioblastoma (GBM) remains unsatisfactory. Lactylation, a recently identified post-translational modification (PTM), has emerged as a critical regulator in multiple human malignancies. Notably, GBM is characterized by enhanced glycolysis and substantial lactate accumulation, prompting us to investigate whether and how lactylation contributes to the initiation and progression of GBM. This may lay a theoretical foundation for the development of potential therapeutic strategies against GBM. In vitro and in vivo experiments were applied to dissect the molecular mechanism whereby histone lactylation H3K18la promotes GBM progression. Specifically, immunoblotting was conducted to evaluate the lactylation levels in GBM cells and tissues. Tissue microarray combined with immunohistochemistry (IHC) staining was utilized to analyze the correlation between lactylation levels and tumor grades. Cell proliferative potential was assessed via the CCK-8 and colony formation assays, whereas wound healing and transwell assays were applied to evaluate cell migratory capacity. Complementing these in vitro observations, in vivo experiments further validated GBM-related phenotypes. Moreover, multi-omics profiling, immunoblotting, quantitative real-time PCR (RT-qPCR), ChIP-qPCR as well as dual luciferase reporter assay were implemented to dissect and verify the molecular mechanism mediated by H3K18la in GBM. Gliomas exhibit prominent lactylation, whose levels are significantly positively correlated with tumor grades and culminate in GBM. Suppression of lactylation, especially H3K18la, markedly impaies the proliferative and migratory capacities of GBM both in vitro and in vivo. Mechanistically, H3K18la drives GBM progression by attaching to HMGA1 promoter and consequently activating HMGA1 transcription. HMGA1 in turn reinforces glycolysis by directly upregulating the glycolytic enzymes LDHA and HK2, which further elevates H3K18la levels and establishes a positive feedback loop. This study explores and refines the biological significance of histone lactylation mark H3K18la in GBM progression. We identify the critical role of the H3K18la–HMGA1–glycolysis–H3K18la positive feedback loop in governing the malignant phenotypes of GBM. These findings may provide a theoretical basis for the development of novel therapeutic interventions against GBM.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: